anifrolumab
Sponsor Astrazeneca PLC · listed as AZN
anifrolumab is a drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Feb 23, 2027 (day precision, medium confidence), tied to trial NCT05138133. That trial is in Phase 3 and currently active not recruiting, studying Lupus Nephritis. It appears across 6 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for anifrolumab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT04877691 | Phase 3 | Active, not recruiting | 2025-08-22 | Experimental | AstraZeneca | Systemic Lupus Erythematosus |
| NCT05138133 catalyst | Phase 3 | Active, not recruiting | 2027-02-23 | Experimental | AstraZeneca | Lupus Nephritis |
| NCT07751848 | Phase 3 | Recruiting | 2028-08-25 | Experimental | AstraZeneca | Lupus Erythematosus, Systemic |
| NCT05835310 | Phase 3 | Recruiting | 2028-10-05 | Experimental | AstraZeneca | Systemic Lupus Erythematosus |
| NCT07430306 | Phase 3 | Recruiting | 2029-01-26 | Other | AstraZeneca | Systemic Lupus Erythematosus |
| NCT07691970 | Phase 3 | Recruiting | 2032-12-30 | Experimental | AstraZeneca | Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More AZN catalysts